Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]
Awaiting development
Reference number: GID-TA11222
Expected publication date: TBC
Please note that ID6206 and ID6146 have now been combined into one appraisal. The new ID number is ID6428 'Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence' - please refer to ID6428 number for further information on these appraisals.